1. Home
  2. AIEV vs APM Comparison

AIEV vs APM Comparison

Compare AIEV & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIEV
  • APM
  • Stock Information
  • Founded
  • AIEV 2011
  • APM 2010
  • Country
  • AIEV United States
  • APM United Kingdom
  • Employees
  • AIEV N/A
  • APM N/A
  • Industry
  • AIEV Blank Checks
  • APM Biotechnology: Pharmaceutical Preparations
  • Sector
  • AIEV Finance
  • APM Health Care
  • Exchange
  • AIEV Nasdaq
  • APM Nasdaq
  • Market Cap
  • AIEV 6.9M
  • APM 5.6M
  • IPO Year
  • AIEV N/A
  • APM 2018
  • Fundamental
  • Price
  • AIEV $0.02
  • APM $0.99
  • Analyst Decision
  • AIEV
  • APM
  • Analyst Count
  • AIEV 0
  • APM 0
  • Target Price
  • AIEV N/A
  • APM N/A
  • AVG Volume (30 Days)
  • AIEV 409.8K
  • APM 138.3K
  • Earning Date
  • AIEV 05-15-2025
  • APM 05-06-2025
  • Dividend Yield
  • AIEV N/A
  • APM N/A
  • EPS Growth
  • AIEV N/A
  • APM N/A
  • EPS
  • AIEV N/A
  • APM 0.00
  • Revenue
  • AIEV N/A
  • APM N/A
  • Revenue This Year
  • AIEV N/A
  • APM $157,729.10
  • Revenue Next Year
  • AIEV N/A
  • APM N/A
  • P/E Ratio
  • AIEV N/A
  • APM $270.99
  • Revenue Growth
  • AIEV N/A
  • APM N/A
  • 52 Week Low
  • AIEV $0.05
  • APM $0.46
  • 52 Week High
  • AIEV $12.12
  • APM $7.49
  • Technical
  • Relative Strength Index (RSI)
  • AIEV N/A
  • APM 51.54
  • Support Level
  • AIEV N/A
  • APM $0.79
  • Resistance Level
  • AIEV N/A
  • APM $0.97
  • Average True Range (ATR)
  • AIEV 0.00
  • APM 0.12
  • MACD
  • AIEV 0.00
  • APM 0.02
  • Stochastic Oscillator
  • AIEV 0.00
  • APM 33.74

About AIEV Thunder Power Holdings Inc. Common Stock

Thunder Power Holdings Inc is engaged in the design and development of high-performance electric vehicles.

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Share on Social Networks: